Story
Nuvation Bio Stock Surges on Early FDA Label Approval for Cancer Drug IBTROZI
Summary
Shares of Nuvation Bio (NUVB) jumped after the U.S. Food and Drug Administration approved an updated label for its lung cancer therapy, IBTROZI, four months ahead of schedule.
Shares of Nuvation Bio (NUVB) surged 5.2% to $6.08 in morning trading after the U.S. Food and Drug Administration (FDA) granted an early approval for an updated label on its lead lung cancer drug, IBTROZI (taletrectinib), significantly strengthening the therapy's long-term efficacy data.
FDA Grants Early Label Update
The FDA's decision came four months ahead of the originally scheduled Prescription Drug User Fee Act (PDUFA) date. The approval incorporates updated clinical trial data with a median follow-up of approximately 51 months, according to Investing.com.
This new label adds 14 months of additional durability evidence for IBTROZI, a ROS1 inhibitor for non-small cell lung cancer. Crucially, it establishes a median duration of response of 49.7 months in tyrosine kinase inhibitor (TKI)-naïve patients, a key metric for demonstrating the drug's long-term effectiveness.
AdAnalyst Confidence and Market Reaction
Adding to the positive momentum, Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and a $10.00 price target for Nuvation Bio. A note from the analyst highlighted IBTROZI's competitive advantage in the ROS1 inhibitor market.
Citizens characterized IBTROZI as having a roughly two-year head start over rival drugs from Nuvalent and GlaxoSmithKline, whose clinical data was described as more immature. The company-specific catalysts were amplified by a constructive market backdrop, with the S&P 500 and Nasdaq Composite both trading higher, providing a supportive environment for biotech stocks.
Read next
More on Stocks
Record Diesel Prices Squeeze US Farmers, Threaten Higher Food Inflation
US farmers are facing record-high diesel costs during the crucial harvest season, a development that is squeezing profit margins and expected to push consumer food prices higher across the supply chain.
US Draft Rules to Permit Most Pharma Licensing Deals with China, Sources Say
The U.S. Treasury Department is reportedly drafting rules that would allow American pharmaceutical companies to continue most licensing deals with Chinese firms, sources say, avoiding broad restrictions sought by some lawmakers over national security concerns.
Century Aluminum's $4B Oklahoma Smelter Project Stalled by Local Opposition
A proposed $4 billion aluminum smelter in Oklahoma, backed by Century Aluminum and Emirates Global Aluminium, faces a prolonged local moratorium and a public referendum, creating significant uncertainty despite a key political victory for its supporters.
BofA Upgrades Equinor to 'Buy' on Bullish European Gas Price Forecast
BofA Securities raised its rating on Equinor to "Buy" from "Neutral," citing an improved outlook for European gas prices that is expected to significantly boost the energy company's cash flow. The bank also increased its price target to 465 Norwegian kroner.